key: cord-0718112-fuumrl43
authors: Nagabhushana, Prerana; Sarkar, Avir; Wadhawan, Isha
title: Letter to the Editor RE: COVID-19 vaccination during pregnancy: Coverage and Safety
date: 2021-10-23
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2021.10.027
sha: 91ffad8fa189327a61c25263e4b3d77aff32ae02
doc_id: 718112
cord_uid: fuumrl43

nan

During Pregnancy: Coverage and Safety" by Blakeway et al. 1 and we appreciate the authors 30 for conducting this study at a particularly crucial point of time to make vaccine safety data 31 available for clinicians. We, however, would like to make some observations to help better 32 comprehend the study. 33

The study reveals that among the vaccinated antenatal population, 3 eventually developed 34 SARS-CoV-2 infection. It would be highly informative if you could further elaborate on the 35 duration between administration of vaccine and development of infection, type of vaccine 36

given and the severity of disease in these women. It is also mentioned that vaccine was 37 administered to one woman with underlying cardiac disease. We would like to know the 38 particulars of the lesion and whether any thromboprophylaxis was given post-vaccination. 39

Among the unvaccinated population, Table 3 states that one woman had a stillbirth. It would 40 be highly appreciable if we are allowed to know the cause of the same, in particular whether it 41 was related to SARS-Cov-2 infection or febrile illness. 42

We also seek come clarifications regarding a few statistical figures. Table 3 shows the perinatal 43 outcomes among women who received vaccine antenatally versus those who did not. Among 44 the 133 women who received at least one dose during pregnancy, 3 developed SARS-CoV-2 45 infection, who when excluded make a cohort of 130. However, in Table S1 , the strength of this 46 cohort is 131.

Assuming that Table S1 is a subset of Table 3 , it is confusing to us that the number of women 48 who had fetal abnormalities (12 vs 11), Caesarean deliveries (133 vs 122) and neonatal 49 intensive care unit admissions (23 vs 21) among unvaccinated women in Table S1 exceeds that of Table 3 . We would be grateful to you if you could shed some light on the same. 51

Also under the results section, it is stated that there was statistically significant trend of reduced 52 vaccine uptake among the Afro-Caribbean and Asian ethnicity compared to Caucasian 53 background (Page 14, Line 25). However, the p value for Asian ethnicity was 0.183, which 54

was not statistically significant. 55

We would also like to know the background behind choosing a cut-off of blood loss of 1 litre 56 as the definition of post-partum hemorrhage. It would significantly exclude many cases falling 57 between 1 litre and the WHO-defined cut-off of 500 mL for vaginal deliveries 2 . 58 59

The authors report no conflict of interest 60

Vaccination During Pregnancy: Coverage and Safety

2) WHO recommendations on prevention and treatment of postpartum haemorrhage